Step Pharma is developing novel therapeutics that inhibit the enzyme CTP Synthase 1 (CTPS1). Its most advanced programme is STP938 which is being developed as a targeted therapy for T-cell malignancies. Step Pharma was created on the basis of research on genetic immunodeficiencies led by Prof. Alain Fischer at the Imagine Institute (Paris, France) which established the essential role of CTPS1 in T- and B-cell proliferation.
